Impact of autoimmune diseases on risk of pancreatic endocrine and exocrine diseases: a prospective cohort study based on the UK Biobank

ZHANG Jingjing; YUAN Chenchen; LU Guotao; XIAO Weiming; GONG Weijuan; FENG Xuebing

doi:10.7619/jcmp.20245503

Journal of Clinical Medicine in Practice > 2025 > 29(7): 1-7, 12. > DOI: 10.7619/jcmp.20245503

ZHANG Jingjing, YUAN Chenchen, LU Guotao, XIAO Weiming, GONG Weijuan, FENG Xuebing. Impact of autoimmune diseases on risk of pancreatic endocrine and exocrine diseases: a prospective cohort study based on the UK Biobank[J]. Journal of Clinical Medicine in Practice, 2025, 29(7): 1-7, 12. DOI: 10.7619/jcmp.20245503

Citation:

PDF (1477 KB)

Impact of autoimmune diseases on risk of pancreatic endocrine and exocrine diseases: a prospective cohort study based on the UK Biobank

ZHANG Jingjing¹,
YUAN Chenchen^{2, 3},
LU Guotao^{2, 3},
XIAO Weiming^{2, 3},
GONG Weijuan^{2, 3},
FENG Xuebing^1,

1.
Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, Jiangsu, 210000
2.
Department of Gastroenterology, the Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225000
3.
Yangzhou Key Laboratory of Pancreatic Disease, Yangzhou, Jiangsu, 225000

More Information

Received Date: November 11, 2024
Revised Date: February 15, 2025

Graphical Abstract

Abstract

Abstract

Objective
To analyze the correlations of autoimmune diseases (AIDs) with the risk of developing pancreatic endocrine and exocrine diseases.
Methods
A total of 451, 497 participants from the UK Biobank were recruited, with the primary outcomes being pancreatic endocrine and exocrine diseases. International Classification of Diseases 9/10 (ICD9/10) codes were used to define each AIDs, the pancreatic endocrine and exocrine diseases. Multivariable Cox proportional hazards models were employed to assess the relationships between AIDs and pancreatic endocrine and exocrine diseases, with adjustments for age, gender, ethnicity, Townsend deprivation index, smoking, alcohol consumption, body mass index, waist circumference, hip circumference, hypertension, dyslipidemia, and gallstones.
Results
A total of 415, 497 participants were included, among which 37, 482 developed pancreas-related diseases during follow-up. Among patients with AIDs, the proportions of those with pancreatic exocrine and endocrine diseases were significantly increased (P < 0.05). Rheumatoid arthritis [HR(95%CI): 1.438(1.161 to 1.781)], ankylosing spondylitis [HR(95%CI): 1.675(1.009 to 2.780)], ulcerative colitis [HR(95%CI): 1.335(1.037 to 1.719)], and Crohn's disease [HR(95%CI): 1.530(1.154 to 2.028)] were all associated with an increased risk of developing pancreatic exocrine diseases (all P < 0.05); additionally, rheumatoid arthritis [HR(95%CI): 1.119(1.004 to 1.248)], ulcerative colitis [HR(95%CI): 1.324(1.175 to 1.491)], systemic sclerosis [HR(95%CI): 2.08(1.355 to 3.191)], and Crohn's disease[HR(95%CI): 1.394(1.197 to 1.624)] were also associated with an increased risk of developing pancreatic endocrine diseases (all P < 0.05).
Conclusion
Overall AIDs and some specific AIDs are associated with an increased risk of developing pancreatic endocrine and exocrine diseases, and early prevention of pancreatic diseases in patients with AIDs should be emphasized in clinical practice.
- autoimmune diseases,
- pancreas,
- endocrine diseases,
- exocrine diseases,
- UK Biobank,
- rheumatoid arthritis,
- ankylosing spondylitis,
- Crohn's disease

FullText(HTML)

References (29)

References

[1]	张佳旭, 杨婷, 李燃. 中老年重症急性胰腺炎患者住院期间死亡预测模型的构建与验证[J]. 实用临床医药杂志, 2024, 28(17): 51-55. doi: 10.7619/jcmp.20241933
[2]	HOQUE R, MALIK A F, GORELICK F, et al. Sterile inflammatory response in acute pancreatitis[J]. Pancreas, 2012, 41(3): 353-357. doi: 10.1097/MPA.0b013e3182321500
[3]	WATANABE T, KUDO M, STROBER W. Immunopathogenesis of pancreatitis[J]. Mucosal Immunol, 2016, 10(2): 283-298.
[4]	GUKOVSKY I, LI N, TODORIC J, et al. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer[J]. Gastroenterology, 2013, 144(6): 1199-1209. e4. doi: 10.1053/j.gastro.2013.02.007
[5]	HAYTER S M, COOK M C. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease[J]. Autoimmun Rev, 2012, 11(10): 754-765. doi: 10.1016/j.autrev.2012.02.001
[6]	XIANG Y, ZHANG M X, JIANG D, et al. The role of inflammation in autoimmune disease: a therapeutic target[J]. Front Immunol, 2023, 14: 1267091. doi: 10.3389/fimmu.2023.1267091
[7]	GOBELET C, GERSTER J C, RAPPOPORT G, et al. A controlled study of the exocrine pancreatic function in Sj?gren's syndrome and rheumatoid arthritis[J]. Clin Rheumatol, 1983, 2(2): 139-143. doi: 10.1007/BF02032170
[8]	TÉL B, STUBNYA B, GEDE N, et al. Inflammatory bowel diseases elevate the risk of developing acute pancreatitis: a meta-analysis[J]. Pancreas, 2020, 49(9): 1174-1181. doi: 10.1097/MPA.0000000000001650
[9]	DESSEIN P H, JOFFE B I. Insulin resistance and impaired beta cell function in rheumatoid arthritis[J]. Arthritis Rheum, 2006, 54(9): 2765-2775. doi: 10.1002/art.22053
[10]	GARCÍA-CARRASCO M, MENDOZA-PINTO C, MUNGUÍA-REALPOZO P, et al. Insulin resistance and diabetes mellitus in patients with systemic lupus erythematosus[J]. Endocr Metab Immune Disord Drug Targets, 2023, 23(4): 503-514. doi: 10.2174/1871530322666220908154253
[11]	DONG X W, ZHU Q T, YUAN C C, et al. Associations of intrapancreatic fat deposition with incident diseases of the exocrine and endocrine pancreas: a UK biobank prospective cohort study[J]. Am J Gastroenterol, 2024, 119(6): 1158-1166. doi: 10.14309/ajg.0000000000002792
[12]	GUKOVSKAYA A S, GUKOVSKY I, ALGVL H, et al. Autophagy, inflammation, and immune dysfunction in the pathogenesis of pancreatitis[J]. Gastroenterology, 2017, 153(5): 1212-1226. doi: 10.1053/j.gastro.2017.08.071
[13]	REN W X, ZHAO L, SUN Y, et al. HMGB1 and toll-like receptors: potential therapeutic targets in autoimmune diseases[J]. Mol Med, 2023, 29(1): 117. doi: 10.1186/s10020-023-00717-3
[14]	CHANG C C, CHIOU C S, LIN H L, et al. Increased risk of acute pancreatitis in patients with rheumatoid arthritis: a population-based cohort study[J]. PLoS One, 2015, 10(8): e0135187. doi: 10.1371/journal.pone.0135187
[15]	ALKHAYYAT M, ABOU SALEH M, GREWAL M K, et al. Pancreatic manifestations in rheumatoid arthritis: a national population-based study[J]. Rheumatology: Oxford, 2021, 60(5): 2366-2374. doi: 10.1093/rheumatology/keaa616
[16]	MONTENEGRO M L, CORRAL J E, LUKENS F J, et al. Pancreatic disorders in patients with inflammatory bowel disease[J]. Dig Dis Sci, 2022, 67(2): 423-436. doi: 10.1007/s10620-021-06899-2
[17]	MASSIRONI S, FANETTI I, VIGANÒ C, et al. Systematic review-pancreatic involvement in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2022, 55(12): 1478-1491. doi: 10.1111/apt.16949
[18]	PEDERSEN J E, ÄNGQUIST L H, JENSEN C B, et al. Risk of pancreatitis in patients with inflammatory bowel disease - a meta-analysis[J]. Dan Med J, 2020, 67(3): A08190427.
[19]	李金强, 惠亮亮. 急性胰腺炎患者肠道菌群的研究进展[J]. 中国微生态学杂志, 2024, 36(12): 1480-1484.
[20]	NAVARRO J F, MORA C. Role of inflammation in diabetic complications[J]. Nephrol Dial Transplant, 2005, 20(12): 2601-2604. doi: 10.1093/ndt/gfi155
[21]	ROHM T V, MEIER D T, OLEFSKY J M, et al. Inflammation in obesity, diabetes, and related disorders[J]. Immunity, 2022, 55(1): 31-55. doi: 10.1016/j.immuni.2021.12.013
[22]	NIE Y Q, ZHOU H T, WANG J, et al. Association between systemic immune-inflammation index and diabetes: a population-based study from the NHANES[J]. Front Endocrinol (Lausanne), 2023, 14: 1245199. doi: 10.3389/fendo.2023.1245199
[23]	WU D, LAN Y L, CHEN S H, et al. Combined effect of adiposity and elevated inflammation on incident type 2 diabetes: a prospective cohort study[J]. Cardiovasc Diabetol, 2023, 22(1): 351. doi: 10.1186/s12933-023-02067-0
[24]	MA X L, CHEN Z J, WANG L, et al. The pathogenesis of diabetes mellitus by oxidative stress and inflammation: its inhibition by berberine[J]. Front Pharmacol, 2018, 9: 782. doi: 10.3389/fphar.2018.00782
[25]	DUBREUIL M, RHO Y H, MAN A D, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study[J]. Rheumatology (Oxford), 2014, 53(2): 346-352. doi: 10.1093/rheumatology/ket343
[26]	TIAN Z X, MCLAUGHLIN J, VERMA A, et al. The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis[J]. Cardiovasc Endocrinol Metab, 2021, 10(2): 125-131. doi: 10.1097/XCE.0000000000000244
[27]	SANG M M, SUN Z L, WU T Z. Inflammatory bowel disease and diabetes: is there a link between them[J]. World J Diabetes, 2022, 13(2): 126-128. doi: 10.4239/wjd.v13.i2.126
[28]	JESS T, JENSEN B W, ANDERSSON M, et al. Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study[J]. Clin Gastroenterol Hepatol, 2020, 18(4): 881-888. e1. doi: 10.1016/j.cgh.2019.07.052
[29]	JASSER-NITSCHE H, BECHTOLD-DALLA POZZA S, BINDER E, et al. Comorbidity of inflammatory bowel disease in children and adolescents with type 1 diabetes[J]. Acta Paediatr, 2021, 110(4): 1353-1358. doi: 10.1111/apa.15643

[1]	MIAO Rui, ZHANG Man, WANG Xuezhi, HAO Yafeng, LIN Li, QUAN Huijuan. Relationship of impaired glucose regulation with slow flow or no reflow during percutaneous coronary intervention in patients with ST segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 40-44, 51. DOI: 10.7619/jcmp.20234122
[2]	ZHANG Li, WANG Lin, HE Wei. Relationships of serum S100 calcium binding protein A8 and S100 calcium binding protein A9 levels with thrombus burden in patients with acute ST-segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 37-42. DOI: 10.7619/jcmp.20232069
[3]	ZOU Yue, CHEN Xufeng. Application of extracorporeal membrane oxygenation in high-risk percutaneous coronary intervention without obvious shock[J]. Journal of Clinical Medicine in Practice, 2022, 26(12): 139-143. DOI: 10.7619/jcmp.20220164
[4]	LIU Qi, JIA Yunshi, SONG Wenting, LI Wuwei. Effects of Zhima Xiaotan Huoxue Recipe on no-reflow and prognosis after percutaneous coronary intervention in low-risk non-ST-elevation acute coronary syndrome patients[J]. Journal of Clinical Medicine in Practice, 2021, 25(24): 69-73. DOI: 10.7619/jcmp.20212580
[5]	ZHANG Jiangang, DAI Shipeng, LIU Hua, MA Zengcai, LIU Juan, XU Zesheng. Effect of percutaneous coronary intervention guided by intravascular ultrasound in treatment of patientswith borderline lesions of non-ST elevated acute coronary syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(15): 53-56. DOI: 10.7619/jcmp.20211247
[6]	LIN Lingdan, XU Shida, XING Haiyan. Value of serum interleukin-17 in predicting slow flow or no reflow after percutaneous coronary intervention in patients with ST-elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2021, 25(11): 93-95, 100. DOI: 10.7619/jcmp.20210482
[7]	WANG Huan, WANG Haibo. Effect of ticagrelor for acute non-ST-segment elevation myocardial infarction patents underwent percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2019, 23(20): 19-21, 24. DOI: 10.7619/jcmp.201920005
[8]	ZHOU Yingfeng. Effect of atorvastatin on no-reflow phenomenon after emergency percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2019, (2): 40-43. DOI: 10.7619/jcmp.201902012
[9]	LI Wenhua, HE Guoping, LI Yong. Application value of Rho-kinase inhibitor in acute coronary syndrome patients with percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2016, (19): 12-15. DOI: 10.7619/jcmp.201619004
[10]	SANG Caidi, ZHANG Yisheng. Observation of coronary arterial injection of tirofiban on prevention of no reflow phenomenon in emergency treatment of patients with percutaneous coronary intervention and related nursing measures[J]. Journal of Clinical Medicine in Practice, 2013, (18): 60-62. DOI: 10.7619/jcmp.201318026

Cited By

Cited by

Periodical cited type(3)

1.	宋尚明. 独活寄生汤联合BKA治疗中老年重度双间室膝关节骨关节炎的效果. 中国医学创新. 2024(03): 90-94 .
2.	梁竹君，肖芮. 蠲痹汤加减治疗活动期类风湿关节炎临床观察. 山西中医. 2024(03): 16-18 .
3.	关岳，李新，杨贺旻，徐思宇，史丽东，刘扬洋，孔令丹，秦影. IRF9、PSMA5联合外周血巨噬细胞M1/M2极化状态预测类风湿性关节炎进展的多元回归模型. 中华养生保健. 2024(19): 4-8 .

Other cited types(1)

Get Citation

PDF

XML

Article views (78) PDF downloads (26) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Impact of autoimmune diseases on risk of pancreatic endocrine and exocrine diseases: a prospective cohort study based on the UK Biobank